Fennec Pharmaceuticals (FENC)
Commercializes PEDMARK for pediatric cisplatin-related hearing-loss protection.
$12.33
At close+0.29 (+2.45%)
Something off on this page? Send us feedback.
Next report
Nov 12, 2026
in 70 days
EPS estimate
$0.10
Revenue estimate
$19.0M
Fiscal quarter
Q3 FY26
EPSReportedEstimate
Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported−$0.06−$0.04−$0.11−$0.02−$0.11$0.01$0.05Pending
Estimate$0.56−$0.12−$0.06−$0.08$0.03−$0.02$0.02$0.10
Surprise−110.7%+66.7%−83.3%+75.0%−466.7%+150.0%+150.0%—
RevenueReportedEstimate
Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported$7.9M$8.8M$9.7M$12.5M$13.8M$15.1M$17.9MPending
Estimate$7.8M$9.0M$9.6M$14.7M$14.7M$13.9M$16.2M$19.0M
Surprise+1.6%−3.2%+0.9%−15.2%−6.5%+8.6%+10.3%—
History
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Nov 2026 | $0.10 | — | — |
| Aug 2026 | $0.02 | $0.05 | +150.0% |
| May 2026 | −$0.02 | $0.01 | +150.0% |
| Mar 2026 | $0.03 | −$0.11 | −466.7% |
| Nov 2025 | −$0.08 | −$0.02 | +75.0% |
The latest year is open to everyone — the 41 quarters behind it read with an account. Sign in | |||
| Aug 2025 | |||
| May 2025 | |||
| Mar 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Mar 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Mar 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Feb 2022 | |||
| Nov 2021 | |||
| Aug 2021 | |||
| May 2021 | |||
| Mar 2021 | |||
| Nov 2020 | |||
| Aug 2020 | |||
| May 2020 | |||
| Feb 2020 | |||
| Nov 2019 | |||
| Aug 2019 | |||
| May 2019 | |||
| Mar 2019 | |||
| Nov 2018 | |||
| Aug 2018 | |||
| May 2018 | |||
| Mar 2018 | |||
| Nov 2017 | |||
| Aug 2017 | |||
| May 2017 | |||
| Mar 2017 | |||
| Nov 2016 | |||
| Aug 2016 | |||
| May 2016 | |||
| Mar 2016 | |||
| Nov 2015 | |||
| Aug 2015 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Nov 12, 2026 | $0.10 | — | — | $19.0M | — | — | — |
| Aug 11, 2026 | $0.02 | $0.05 | +150.0% | $16.2M | $17.9M | +10.3% | +16.8% |
| May 14, 2026 | −$0.02 | $0.01 | +150.0% | $13.9M | $15.1M | +8.6% | +5.5% |
| Mar 24, 2026 | $0.03 | −$0.11 | −466.7% | $14.7M | $13.8M | −6.5% | +2.5% |
| Nov 13, 2025 | −$0.08 | −$0.02 | +75.0% | $14.7M | $12.5M | −15.2% | +2.2% |
The latest year is open to everyone — the 41 quarters behind it read with an account. Sign in | |||||||
| Aug 14, 2025 | |||||||
| May 13, 2025 | |||||||
| Mar 10, 2025 | |||||||
| Nov 7, 2024 | |||||||
| Aug 13, 2024 | |||||||
| May 14, 2024 | |||||||
| Mar 21, 2024 | |||||||
| Nov 6, 2023 | |||||||
| Aug 3, 2023 | |||||||
| May 11, 2023 | |||||||
| Mar 30, 2023 | |||||||
| Nov 11, 2022 | |||||||
| Aug 12, 2022 | |||||||
| May 12, 2022 | |||||||
| Feb 28, 2022 | |||||||
| Nov 10, 2021 | |||||||
| Aug 10, 2021 | |||||||
| May 13, 2021 | |||||||
| Mar 30, 2021 | |||||||
| Nov 16, 2020 | |||||||
| Aug 5, 2020 | |||||||
| May 14, 2020 | |||||||
| Feb 14, 2020 | |||||||
| Nov 12, 2019 | |||||||
| Aug 9, 2019 | |||||||
| May 9, 2019 | |||||||
| Mar 13, 2019 | |||||||
| Nov 13, 2018 | |||||||
| Aug 13, 2018 | |||||||
| May 14, 2018 | |||||||
| Mar 26, 2018 | |||||||
| Nov 13, 2017 | |||||||
| Aug 11, 2017 | |||||||
| May 12, 2017 | |||||||
| Mar 29, 2017 | |||||||
| Nov 14, 2016 | |||||||
| Aug 12, 2016 | |||||||
| May 12, 2016 | |||||||
| Mar 28, 2016 | |||||||
| Nov 12, 2015 | |||||||
| Aug 11, 2015 | |||||||